A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations.
This report summarizes the findings of a national survey of infectious diseases consultants regarding their use of neuraminidase inhibitors and the status of their planning for an influenza pandemic. The respondents indicated that government stockpiles should be increased, that many have received requests for antiviral medications, and that additional recommendations regarding the appropriate use of antiviral medications would be helpful.
Ortiz
Justin R
JR
Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. dzv3@cdc.gov
Shay
David K
DK
Liedtke
Laura A
LA
Bresee
Joseph S
JS
Strausbaugh
Larry J
LJ
D000998:Antiviral Agents / Q000627:therapeutic use; D003141:Communicable Diseases; D021821:Communicable Diseases, Emerging; D003430:Cross-Sectional Studies; D004196:Disease Outbreaks; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D019538:Health Care Surveys; D006285:Health Planning; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D010818:Practice Patterns, Physicians'; D012955:Societies, Medical; D014481:United States
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D009439:Neuraminidase